Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OBI.L
SELLREMOVEOndine Biomedical Inc. · Healthcare · Canada · $101M · Avg Vol: $80K/d
Ondine Biomedical is a micro-cap life sciences firm with a very low quality score of 10. It lacks the scale, financial strength, and market adoption required to justify an investment.
COMPANY DESCRIPTION
Ondine Biomedical Inc. is a biotechnology company that develops photodisinfection therapies to prevent and treat multi-drug resistant infections, notably its Steriwave nasal decolonization system. Its proprietary, non-antibiotic platform technology destroys pathogens instantly without generating antimicrobial resistance, offering a critical tool for hospital infection control. Ondine is a pioneer in light-activated antimicrobial therapies, targeting the global healthcare-associated infection market.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|
| Revenue | 1.8M | 0.5M | 0.8M | 1.4M | -7.3% |
| EPS | -0.17 | -0.03 | -0.02 | -0.05 | — |
| Shares | 519.6M | 519.6M | 519.6M | 442.0M | -14.9% |
| Debt | 0.5M | 0.6M | 0.4M | 0.1M | -39.0% |
| Equity | 20.9M | 8.2M | 1.5M | 4.9M | -38.6% |
| Op CF | -8.8M | -11.5M | -9.6M | -10.9M | — |
| Inv CF | -54,342 | -0.2M | -0.1M | -7,057 | — |
| Fin CF | 29.6M | -0.2M | 2.7M | 15.3M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OBI.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OBI.L | Ondine Biomedical Inc.(you) | $101M | 20 | SELL |
| PMN | ProMIS Neurosciences, Inc. | $97M | 15 | STRONG SELL |
| EDSA | Edesa Biotech, Inc. | $61M | 17 | STRONG SELL |
| MSLE | Satellos Bioscience Inc. | $119M | 10 | STRONG SELL |
| ENGN | enGene Therapeutics Inc. | $114M | 8 | STRONG SELL |
| MIST | Milestone Pharmaceuticals Inc. | $161M | 1 | STRONG SELL |
| HELP | Cybin D/B/A Helus Pharma | $245M | 6 | STRONG SELL |
| EPRX | Eupraxia Pharmaceuticals Inc. | $425M | 25 | SELL |
| TELI.CN | Telescope Innovations Corp. | $49M | 40 | HOLD |
| QNTM.CN | Quantum BioPharma Ltd. | $45M | 2 | STRONG SELL |
Peer medians: ROE -42.2% · P/E 14.3x · Gross margin 32.9%